These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 19628430)

  • 41. [Angiogenesis and anti-angiogenic strategies for glioblastoma].
    de Boüard S; Guillamo JS
    Bull Cancer; 2005 Apr; 92(4):360-72. PubMed ID: 15888393
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Bevacizumab on the PBS.
    Kingston D
    Aust Fam Physician; 2007 Sep; 36(9):680. PubMed ID: 17915374
    [No Abstract]   [Full Text] [Related]  

  • 43. A multilayer grow-or-go model for GBM: effects of invasive cells and anti-angiogenesis on growth.
    Saut O; Lagaert JB; Colin T; Fathallah-Shaykh HM
    Bull Math Biol; 2014 Sep; 76(9):2306-33. PubMed ID: 25149139
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Mixed news for Avastin.
    Mack GS
    Nat Biotechnol; 2009 Jun; 27(6):494. PubMed ID: 19513035
    [No Abstract]   [Full Text] [Related]  

  • 45. Recurrent glioblastoma multiforme: advances in treatment and promising drug candidates.
    Simpson L; Galanis E
    Expert Rev Anticancer Ther; 2006 Nov; 6(11):1593-607. PubMed ID: 17134364
    [TBL] [Abstract][Full Text] [Related]  

  • 46. First-line bevacizumab for glioblastoma: what do recent Trail results mean for future treatment?
    Marosi C
    CNS Oncol; 2013 Nov; 2(6):473-4. PubMed ID: 25054815
    [No Abstract]   [Full Text] [Related]  

  • 47. Molecular characteristics and pathways of Avastin for the treatment of glioblastoma multiforme.
    Spasic M; Chow F; Tu C; Nagasawa DT; Yang I
    Neurosurg Clin N Am; 2012 Jul; 23(3):417-27. PubMed ID: 22748654
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Update on the therapeutic approaches to brain tumors.
    Lallana EC; Abrey LE
    Expert Rev Anticancer Ther; 2003 Oct; 3(5):655-70. PubMed ID: 14599089
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Glioblastoma survival in the United States improved after Food and Drug Administration approval of bevacizumab: a population-based analysis.
    Johnson DR; Leeper HE; Uhm JH
    Cancer; 2013 Oct; 119(19):3489-95. PubMed ID: 23868553
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Angiogenesis inhibitor DC101 delays growth of intracerebral glioblastoma but induces morbidity when combined with irradiation.
    Verhoeff JJ; Stalpers LJ; Van Noorden CJ; Troost D; Ramkema MD; van Bree C; Song JY; Donker M; Chekenya M; Vandertop WP; Richel DJ; van Furth WR
    Cancer Lett; 2009 Nov; 285(1):39-45. PubMed ID: 19473756
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Bevacizumab for the treatment of glioblastoma.
    Chowdhary S; Chamberlain M
    Expert Rev Neurother; 2013 Aug; 13(8):937-49. PubMed ID: 23952194
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Bevacizumab for newly diagnosed glioblastoma.
    Gilbert MR; Sulman EP; Mehta MP
    N Engl J Med; 2014 May; 370(21):2048-9. PubMed ID: 24849088
    [No Abstract]   [Full Text] [Related]  

  • 53. Monoclonal antibodies.
    Chiocca EA
    J Neurosurg; 2010 Aug; 113(2):190; discussion 190-1. PubMed ID: 20345220
    [No Abstract]   [Full Text] [Related]  

  • 54. Plants versus tumors: the search for new targets in neuro-oncology.
    Welling LC; Figueiredo EG; Teixeira MJ
    World Neurosurg; 2012 Jul; 78(1-2):7-8. PubMed ID: 22634151
    [No Abstract]   [Full Text] [Related]  

  • 55. Susceptibility-weighted imaging at ultra-high field (7 T) in the evaluation of brain tumors.
    Zee CS; Yan C
    World Neurosurg; 2012; 77(5-6):654-6. PubMed ID: 22381318
    [No Abstract]   [Full Text] [Related]  

  • 56. Targeted therapies: Further delineating bevacizumab's response spectrum.
    Reardon DA; Wen PY
    Nat Rev Clin Oncol; 2014 May; 11(5):243-4. PubMed ID: 24710578
    [No Abstract]   [Full Text] [Related]  

  • 57. Fearful of Avastin's fate, Genentech asks for unusual hearing.
    Ratner M
    Nat Med; 2011 Mar; 17(3):233. PubMed ID: 21383702
    [No Abstract]   [Full Text] [Related]  

  • 58. The avastin story.
    Sekeres MA
    N Engl J Med; 2011 Oct; 365(15):1454-5. PubMed ID: 21995408
    [No Abstract]   [Full Text] [Related]  

  • 59. Bringing the endovascular neurosurgeon into the neuro-oncology treatment team.
    Peruzzi P; Chiocca EA
    World Neurosurg; 2012 Jan; 77(1):59-61. PubMed ID: 22405385
    [No Abstract]   [Full Text] [Related]  

  • 60. Rare serious complications of erlotinib therapy.
    Kapoor S
    Acta Neurochir (Wien); 2013 Apr; 155(4):743. PubMed ID: 23361636
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.